Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes

BMC Pharmacology and Toxicology

Volumn 14, Issue , 2013, Pages

  Urien, Saik ^a,b   Bardin, Christophe ^c   Bader Meunier, Brigitte ^b,d   Mouy, Richard ^d   Compeyrot Lacassagne, Sandrine ^d   Foissac, Franz ^a,b   Florkin, Benoît ^d   Wouters, Carine ^d   Neven, Bénédicte ^b,d   Treluyer, Jean Marc ^a,b,c   Quartier, Pierre ^b,d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c NONE   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ARTICLE; AUTOINFLAMMATORY DISEASE; CHILD; CHILDHOOD DISEASE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; FEMALE; HUMAN; INFANT; JUVENILE RHEUMATOID ARTHRITIS; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD; ALGORITHM; ARTHRITIS, JUVENILE; BIOLOGICAL MODEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; HEREDITARY AUTOINFLAMMATORY DISEASES; METABOLIC CLEARANCE RATE; METABOLISM; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; SYNDROME; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ALGORITHMS; ARTHRITIS, JUVENILE; C-REACTIVE PROTEIN; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; INFANT; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; SYNDROME; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883255531     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-14-40     Document Type: Article

References (10)

1. Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum 2011, 63:314-324. 10.1002/art.30105, 20967858.
2. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L, Schneider R, Berkun Y, Calvo I, Erguven M, Goffin L, Hofer M, Kallinich T, Oliveira SK, Uziel Y, Viola S, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Gamir ML, Kone-Paut I, Grom A, Magnusson B, Ozen S, Sztajnbok F, Lheritier K, Abrams K, Kim D, Martini A, Lovell DJ. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012, 367:2396-2406. 10.1056/NEJMoa1205099, 23252526.
3. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer J-M, Landais P, Pascual V. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011, 70:747-754. 10.1136/ard.2010.134254, 3070271, 21173013.
4. Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loët X, Sibilia J. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008, 67:302-308.
5. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005, 201:1479-1486. 10.1084/jem.20050473, 2213182, 15851489.
6. Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, Pinto G, Pagnier A, Bodemer C, Bodaghi B, Tardieu M, Prieur AM, Quartier P. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010, 62:258-267.
7. Lavielle M, Mentré F. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn 2007, 34:229-249. 10.1007/s10928-006-9043-z, 1974848, 17211713.
8. Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008, 90:154-166. 10.1016/j.cmpb.2007.12.002, 18215437.
9. Ihaka R, Gentleman R. R: A Language for Data Analysis and Graphics. Journal of Computational and Graphical Statistics 1996, 5:299-314.
10. Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008, 48:303-332. 10.1146/annurev.pharmtox.48.113006.094708, 17914927.